Bronnen:
- Dandekar M, D’Cruz AK, Huang SH, et al. General principles of head and neck cancer management. In: O’Sullivan B, Brierly JD, D’Cruz A, Fey MF, Pollock R, Vermorken JB (eds) Manual of Clinical Oncology, Ninth Edition, John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, UK, 2015 pp 503-11.,Machtay M, Moughan J, trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582-9.,Ang KK, Harris J, Wheeler, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.,Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG1016): a randomized, multicenter, non-inferiority trial. Lancet Oncol. published on line November 15, 2018.,Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomized controlled phase 3 trial. Lancet Oncol. published on line November 15, 2018.,Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999; 10: 2493-506.,Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;3564: 567-78.,Pignon JP, le Maître A, Maillard E , Bourhis J, on behalf of the MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother and Oncol. 2009;92:4-14.,Rosenthal DI, Harari PM, Giralt J, et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol. 2016;34:1300-8.,Szturz P, Wouters K, Kiyota N, et al. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Front Oncol. 2019, Febr 21; 9:86. doi: 10.3389/fonc.2019.00086. eCollection 2019.